Research · Sep 3, 2026
[ARGX] argenx Thesis 2026: Vyvgart Indication Expansion Drives FcRn Franchise Leadership
argenx SE (NASDAQ: ARGX) FY2025 revenue ~$3.0-3.4B (+50-65%) with adj. EPS ~$3.50-5.00 reflecting continued Vyvgart (efgartigimod) franchise expansion across generalized myasthenia gravis (gMG) + chronic inflammatory demyelinating polyneuropathy (CIDP) + selected post-2024 immune thrombocytopenia (ITP) BLA submission + selected post-2025 multiple selected various indications under continued CEO Tim Van Hauwermeiren (~17-year tenure since 2008 founding). Global immunology biotech leader focused on developing first-in-class antibody therapies for selected severe autoimmune diseases via SIMPLE Antibody platform. Founded 2008 in Breda Netherlands by Tim Van Hauwermeiren + Hans de Haard + Torsten Dreier + selected various Innogenetics + Stallergenes alumni as Crucell-Belgium spinout (~17-year heritage); selected post-2010 Belgium incorporation + selected post-2014 Euronext Brussels IPO; selected post-May 2017 NASDAQ listing; selected post-December 2021 first FDA approval for Vyvgart in generalized myasthenia gravis (gMG) + selected post-2022 EU + Japan approvals; selected post-June 2023 Vyvgart Hytrulo (subcutaneous formulation) FDA approval; selected post-June 2024 FDA approval for Vyvgart Hytrulo in chronic inflammatory demyelinating polyneuropathy (CIDP) — selected first new CIDP treatment in 30+ years. Headquartered in Amsterdam Netherlands; ~1,500+ employees globally with ~$3.0-3.4B revenue. Single primary product franchise: Vyvgart (efgartigimod) selected first-in-class neonatal Fc receptor (FcRn) antagonist. Vyvgart franchise leadership: ~$3.0-3.4B aggregate revenue FY2025 (~+50-65% YoY); first-in-class FcRn antagonist mechanism reducing pathogenic IgG autoantibodies; gMG ~$1.5-2B aggregate revenue FY2025 (~10,000+ US patients); CIDP ~$0.8-1.2B aggregate revenue FY2025 (post-June 2024 FDA approval ramp; selected first new CIDP treatment in 30+ years); IV + SC formulation expansion (~50-60% Hytrulo subcutaneous mix FY2025). Indication expansion pipeline: Immune Thrombocytopenia (ITP) post-2024 BLA submission; anti-AChR Ab+ ocular myasthenia gravis (OMG) post-2025 readout; Pemphigus post-2025 readout; Sjögren's syndrome post-2026 readout; lupus nephritis post-2026 readout; selected ~10+ pivotal trials covering various autoimmune diseases. SIMPLE Antibody platform + pipeline: ARGX-117 (empasiprubart) complement inhibitor for multifocal motor neuropathy (MMN); ARGX-119 MuSK agonist for myasthenia gravis; selected ~10+ pipeline candidates. CEO Tim Van Hauwermeiren since 2008 founding (~17-year tenure as co-founder + CEO; ex-J&J + ex-Innogenetics + ex-Stallergenes + ~25-year industry career; chemical engineer by training); CFO Karen Massey; CSO Hans de Haard (co-founder). Capital structure: ~$3.5-4B aggregate cash + investments; no dividend; no buybacks (capital priority on growth + R&D investment); ~$1.0-1.2B annual R&D spend; investment-grade B1/B+ credit rating (post-2024 upgrade). FY2026 thesis: Vyvgart franchise leadership + ITP + OMG + Pemphigus + Sjögren's + lupus nephritis indication expansion + Hytrulo mix expansion + SIMPLE Antibody pipeline + FCF positive trajectory. Risks: ~95%+ Vyvgart concentration, indication expansion pivotal trial failures, US Inflation Reduction Act Medicare drug price negotiation + EU pricing pressure, UCB Rystiggo + selected various FcRn antagonist competition, Vyvgart manufacturing scale-up.